MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of ...

Gross SC-islet morphology and size were maintained, yet the fraction of NKX6.1-positive β cells fell substantially, pointing ...

The really important things for hormone health are the things we should all be doing, things that are good for our body — good sleep, a healthy diet, and exercise. Sleep is really important for ...

Crinetics Pharmaceuticals (NASDAQ:CRNX | CRNX Price Prediction) shares have climbed 99% just this week, from $42.03 at Monday ...

A noninvasive blood-based test identified cases of endometriosis that were missed by imaging, data at the Endocrine Society ...

At ENDO 2026, the annual meeting of the Endocrine Society, researchers reported that measuring adrenocorticotropic hormone ...

Vertex claimed the two drugs in the deal could eventually bring in more than $5 billion annually. Still, the high price it ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of ...

One company leads in gene-editing approvals, while the other targets surging demand in metabolic treatments. Here’s how their financials and risk profiles compare.

A new review was published in Volume 18 of Aging on June 11, 2026, titled "Age-related dysfunctions of the neuroendocrine ...

FDA clearance establishes the first CDK4/6 inhibitor indication spanning HR+ metastatic disease regardless of HER2 status, creating a new maintenance strategy for HR+/HER2+ tumors. PATINA randomized ...

Illustration: Kelsea Petersen / The Athletic; Claus Anderson / Getty Images, Cole Burston / Getty Images, Richard Lautens / Getty Images TORONTO — It spoke to the gravity of the situation that he felt ...